Spectral AI, Inc. (MDAIW)

Spectral AI, Inc. (NASDAQ: MDAI; warrant: MDAIW) is a diagnostics company that uses artificial intelligence and multispectral imaging to assess wound healing potential. The firm was founded to commercialize wound-assessment technology that predicts whether burns or other wounds will heal naturally or require intervention, allowing clinicians to make treatment decisions faster and with more objective information than visual examination alone.

The origins: Spectral MD and wound imaging

Spectral AI traces its roots to Spectral MD, a company focused on developing optical imaging technology for burn assessment. Burn care is a challenging clinical domain. Burn wounds vary in depth — some affect only the skin’s outer layers (superficial), while others extend to deeper tissue (full thickness). The distinction is critical because superficial burns heal naturally, while full-thickness burns almost always require skin grafting. Clinicians traditionally make this assessment visually, which is subjective and error-prone, leading to both unnecessary grafts (overtreatment) and delayed treatment (undertreatment).

Spectral MD’s insight was that different tissue depths absorb and reflect different wavelengths of light. By capturing images across multiple wavelengths — multispectral imaging — and applying machine learning algorithms trained on thousands of burn images, the company could teach a computer to classify burn depth more objectively than a trained eye. The technology creates a quantitative assessment tool that clinicians can use to supplement clinical judgment.

From research to government funding

The company spent years developing and validating the wound-assessment technology. Early validation came through clinical research partnerships and small pilot studies. The technology attracted the attention of the U.S. Department of Defense and the Department of Health and Human Services, both of which have long-standing interest in improving battlefield and civilian burn care.

Spectral MD began securing government contracts to fund development. The U.S. government has awarded the company more than $130 million in contracts to develop and expand the wound healing assessment platform. This funding accelerated development and allowed the company to pursue regulatory clearance (FDA approval for clinical use) and to expand the technology beyond burn wounds into other indications, such as diabetic foot ulcers, which represent a large and growing clinical need.

The path to public markets: SPAC combination

In 2023, Spectral MD completed a business combination with Rosecliff Acquisition Corp I, a special purpose acquisition company (SPAC). The merger brought Spectral MD to the public markets under the name Spectral AI, Inc., trading on the NASDAQ under the ticker MDAI starting September 12, 2023. The SPAC deal provided capital and public company status but also came with the obligations of public reporting, board oversight, and shareholder accountability.

The SPAC merger valued the company at a valuation reflecting the promise of the technology and the government contract pipeline. However, the public markets have been sceptical of pre-revenue or early-revenue medical device companies, so the shares have traded below the SPAC’s initial valuation in the periods following the merger, reflecting the challenge of moving a government-funded research programme into commercial adoption.

How the technology works and what it assesses

Spectral AI’s core product captures images of wounds using a handheld multispectral camera that records light intensity across dozens of wavelengths, not just visible light. The camera is non-invasive and requires no contact with the wound. The images are processed by machine learning models trained to identify tissue characteristics associated with deep burns or full-thickness wounds.

The output is a prediction: the likelihood that the wound will heal without intervention, or the probability that skin grafting will be necessary. This prediction is presented to the clinician alongside a visualization of the wound that highlights regions of high versus low healing potential. The system is designed to augment clinical decision-making, not replace it. A clinician reviews the assessment and the imaging and makes the final treatment decision.

The technology is narrowly focused on wound assessment. It does not treat wounds or predict other clinical outcomes (infection risk, pain, cosmetic results). The value proposition rests on the observation that objective assessment of healing potential can change clinical decisions — specifically, the company argues it can reduce unnecessary grafts and accelerate appropriate treatment.

Revenue model and government contracts

Spectral AI generates revenue through two channels, though the mix is heavily weighted toward government. First, government contracts fund development and support procurement of the technology for use by military and civilian healthcare systems. These contracts are multi-year, often with milestones tied to development progress or validation studies. They fund R&D costs and create a dedicated customer base (military hospitals, veteran affairs facilities).

Second, the company can license the technology to civilian hospitals and clinics. Clinical adoption is slower and harder than government procurement because hospital buying processes are lengthy, clinicians must be trained on the technology, and hospital administrators must convince budget committees of the value. Early civilian revenue is modest but growing.

The reliance on government contracts is both an advantage and a risk. Government funding is stable and patient with long development timelines, which allows the company to build durable technology. But government procurement is unpredictable, dependent on appropriations and political priorities. Expansion to civilian markets is essential for long-term sustainability, but it is an expensive and uncertain process.

From burn wounds to broader diagnostics

The company’s original focus is burn-wound assessment, but the strategic goal is to expand the AI platform into other wound indications. Diabetic foot ulcers represent a massive clinical opportunity: more than 10 million people in the United States suffer from diabetes, and many develop foot ulcers. Early detection and intervention can prevent amputation, creating a large addressable market.

The same technology stack — multispectral imaging plus machine learning — can be adapted to diabetic ulcers, which have different optical signatures than burns but share the same underlying principle: wound depth and tissue viability can be assessed optically. Expanding into diabetic ulcers diversifies Spectral AI’s revenue streams and reduces dependence on burn care and government funding.

The company is also exploring other wound types (traumatic wounds, surgical wounds, venous leg ulcers), but validation and regulatory approval for each indication require separate clinical studies and FDA submissions. Each expansion takes years and millions in R&D spending.

The current position: growth through validation and adoption

As of 2026, Spectral AI is in a critical transition phase. The technology has been developed and validated in government-funded studies. The company has regulatory clearance in several indications. The remaining challenges are clinical adoption and revenue growth. The company must prove that the technology reduces unnecessary interventions, improves clinical outcomes, or delivers compelling economic value (cost savings) to justify adoption in civilian hospitals. This requires marketing, clinical education, and sustained customer support.

The company’s public status brings both benefit and pressure. Public capital is more expensive than government grants but more reliable than venture funding. Public reporting creates accountability and visibility, which can accelerate customer decisions or slow them (some hospital systems are conservative about adopting technologies with public market volatility). The share price will track expectations for government contract procurement and civilian adoption rates — both uncertain but material.

How to research Spectral AI as an investment

Spectral AI files quarterly and annual reports with the SEC detailing government contracts and civilian licensing revenue. Watch for announcements of new government contracts or contract expansions, which signal continued federal support. Clinical validation studies (publications in medical journals) are also important — they provide third-party evidence of the technology’s effectiveness.

Track the adoption trajectory among civilian hospitals. Early adoption is typically driven by pioneers — academic medical centres and burn centres with research relationships. The spread beyond these early adopters is the key inflection point. Also monitor progress on expansion into diabetic ulcers and other indications; each new indication is a new growth opportunity but also a new regulatory and reimbursement challenge.

The investment thesis rests on a longer timeline than most biotech companies. Government contracts provide runway, but commercialisation in civilian healthcare is slow. Success requires not just that the technology works, but that hospitals change clinical workflows to adopt it, and that reimbursement (payment from insurance) justifies the equipment and training costs.